BG Medicine Partners with Framingham Study to Track Heart Attack Risk
May 01, 2009
BG Medicine Partners with Framingham Study to Track Heart Attack Risk
Biomarkers
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- BG Medicine Says Data from 6,600-Patient Clinical Study Validates CardioScore Cardiac Risk Test
February 17, 2012 / ProteoMonitor - As BG Medicine Submits Cardio Risk Test to FDA, Some Pharmas See Opportunity for Preventive Therapy
January 11, 2012 / Pharmacogenomics Reporter - BG Medicine Q1 Revenues Fall but Galectin-3 Sales Jump as Company Pursues Expanded Use for Test
May 17, 2012 / ProteoMonitor - BG Medicine Inks CRADA with NHLBI, BU to ID Heart Disease Markers from Framingham Study
March 18, 2009 / Pharmacogenomics Reporter - Pharmas Nudge Semantic Web Technology Toward Practical Drug Discovery Applications
March 6, 2009 / BioInform